ClinicalTrials.gg
CompletedNCT05925049Updated Nov 12, 2026

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

An observational study in Multiple Sclerosis, sponsored by Biogen. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Biogen · Observational

How we know

Updated Nov 12, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
271
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 127 studies in Multiple Sclerosis by Biogen — 2 open to participants now, 4 under way, 1 of them phase 3. Multiple Sclerosis · Biogen.

Enrollment
28th of 48
271 · median 355
Started
2023
with 4 others
Observational
48 of 127
1 open now
Registered
126th of 127
by date

Among the 127 studies in Multiple Sclerosis by Biogen, this one is the 28th largest by enrollment of the 48 observational ones that give a count, is one of 5 that started in 2023, is one of 48 observational ones, and was the 126th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 127 studies in Multiple Sclerosis by Biogen are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Multiple Sclerosis by Biogen, or all of them as a file.
02

Study summary

The primary objective of this study is to estimate the incidence of Anti-Natalizumab Antibodies (ANAs) in the cohort of natalizumab-naïve and other MS monoclonal antibody (mAb)-naive participants who start receiving natalizumab subcutaneous (SC) injections. The secondary objectives of this study are to estimate the proportion of participants detected with ANAs when switched from natalizumab intravenous (IV) to natalizumab SC (natalizumab-experienced cohort); to evaluate serious adverse events (SAEs), including injection reactions and hypersensitivity reactions, by ANA status and to assess the proportion of participants who had MS relapse, by ANA status.

Read the detailed description

The study will collect data prospectively and retrospectively.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will include available EU MS registry participants.

Eligibility criteria

Key Inclusion Criteria:

  • Participants who are natalizumab-naïve and other MS mAb-naive and who start on natalizumab SC.
  • Participants who have previously received natalizumab IV and switch from natalizumab IV to SC administration.

Key Exclusion Criteria :

  • For the natalizumab-naive and other MS mAb-naive cohort, participants who previously received natalizumab or other MS mAbs will be excluded.
  • For the natalizumab-experienced cohort, participants who are naive to natalizumab will be excluded.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
271 participants (actual)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Cohort 1: Naive Participants

    Per standard of care, participants with MS enrolled in selected MS registries, who are natalizumab-naïve and other MS mAb-therapy-naive will receive natalizumab 300 mg, SC injection according to decision of the treating physician.

    Drug: Natalizumab

  • Cohort 2: Natalizumab Experienced

    Per standard of care, participants with MS enrolled in selected MS registries, who have previously received natalizumab IV will be switched from natalizumab IV to SC administration to receive natalizumab 300 mg, SC injection according to decision of the treating physician.

    Drug: Natalizumab

Interventions

  • Administered as specified in the treatment arm.

    Also known as: Tysabri

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Natalizumab-Naive and Other MS mAb-Naive Cohort who Start Taking Natalizumab Injections and Develop Anti-Natalizumab Antibodies (ANAs)

    Time frame: Up to 1.75 years

Secondary outcomes

  1. Percentage of Participants in Natalizumab-Experienced Cohort who Switched From Natalizumab IV Infusion to SC Injection and Develop Anti-Natalizumab Antibodies (ANAs)

    Time frame: Up to 1.75 years

  2. Percentage of Participants With SAEs by Positive (Transient or Persistent) or Negative ANA Status

    SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in permanent or significant damage to health or limitation of capabilities or is manifested as a congenital anomaly or birth defect in offspring, irrespective of the administered dose of the medicinal product.

    Time frame: Up to 1.75 years

  3. Percentage of Participants With MS Relapses by Positive (Transient or Persistent) or Negative ANA Status

    Time frame: Up to 1.75 years

07

Study locations

1 site
  • Research Site
    Cambridge, Massachusetts 02142, United States
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Oct 2026, 39 months.

Of 91 industry-sponsored observational studies under Multiple Sclerosis, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 75. This study's 39 months is below that.

Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2023
First posted
Jun 29, 2023
StartActual
Jun 30, 2023
Primary completionActual
Oct 29, 2026
CompletionActual
Oct 29, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 12, 2026
Primary completion
Oct 31, 2026→Oct 29, 2026 (actual)
Nov 12, 2026
Study completion
Oct 31, 2026→Oct 29, 2026 (actual)
Nov 12, 2026
Enrollment
400 (estimated)→271 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Active, not recruiting→Completed
    Primary completion Oct 31, 2026→Oct 29, 2026 (now actual)
    Study completion Oct 31, 2026→Oct 29, 2026 (now actual)
    Enrollment 400 (estimated)→271 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05925049
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Jun 29, 2023
Start date
Jun 30, 2023
Primary completion
Oct 29, 2026
Completion
Oct 29, 2026
Last update
Nov 12, 2026

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion